1. Home
  2. GLTO vs BAOS Comparison

GLTO vs BAOS Comparison

Compare GLTO & BAOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLTO
  • BAOS
  • Stock Information
  • Founded
  • GLTO 2011
  • BAOS 2018
  • Country
  • GLTO Denmark
  • BAOS China
  • Employees
  • GLTO N/A
  • BAOS N/A
  • Industry
  • GLTO Biotechnology: Pharmaceutical Preparations
  • BAOS Business Services
  • Sector
  • GLTO Health Care
  • BAOS Consumer Discretionary
  • Exchange
  • GLTO Nasdaq
  • BAOS Nasdaq
  • Market Cap
  • GLTO 4.0M
  • BAOS 3.4M
  • IPO Year
  • GLTO 2020
  • BAOS 2021
  • Fundamental
  • Price
  • GLTO $3.29
  • BAOS $3.76
  • Analyst Decision
  • GLTO Buy
  • BAOS
  • Analyst Count
  • GLTO 1
  • BAOS 0
  • Target Price
  • GLTO $10.00
  • BAOS N/A
  • AVG Volume (30 Days)
  • GLTO 86.6K
  • BAOS 4.1M
  • Earning Date
  • GLTO 05-08-2025
  • BAOS 06-17-2025
  • Dividend Yield
  • GLTO N/A
  • BAOS N/A
  • EPS Growth
  • GLTO N/A
  • BAOS N/A
  • EPS
  • GLTO N/A
  • BAOS N/A
  • Revenue
  • GLTO N/A
  • BAOS $624,087.00
  • Revenue This Year
  • GLTO N/A
  • BAOS N/A
  • Revenue Next Year
  • GLTO N/A
  • BAOS N/A
  • P/E Ratio
  • GLTO N/A
  • BAOS N/A
  • Revenue Growth
  • GLTO N/A
  • BAOS N/A
  • 52 Week Low
  • GLTO $2.01
  • BAOS $1.44
  • 52 Week High
  • GLTO $16.07
  • BAOS $13.66
  • Technical
  • Relative Strength Index (RSI)
  • GLTO 59.33
  • BAOS 74.48
  • Support Level
  • GLTO $3.05
  • BAOS $2.27
  • Resistance Level
  • GLTO $3.49
  • BAOS $4.39
  • Average True Range (ATR)
  • GLTO 0.26
  • BAOS 0.33
  • MACD
  • GLTO 0.04
  • BAOS 0.16
  • Stochastic Oscillator
  • GLTO 75.76
  • BAOS 71.23

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

About BAOS Baosheng Media Group Holdings

Baosheng Media Group Holdings Ltd operates as a V-log streaming marketing service provider. The firm offers comprehensive marketing solutions. Its services are Internet effect marketing, V-log or short video streaming marketing including content production and operation, e-commerce marketing, original big data platform system service, and AI technology. It provides one-stop and full-link deep customized marketing solutions for partners. Baosheng Group is also a core agency of domestic Internet companies such as Tencent, Alibaba, Bytedance, and Kuaishou, with performing channel marketing services, technologies, and applications.

Share on Social Networks: